March 2026

PDSB|EPS -$0.74|Net Loss $34.5M Stock $0.54 (-15.4%) Narrower Loss. PDS Biotechnology Corporation (NASDAQ:PDSB) reported a FY 2025 loss per share of -$0.74, reflecting a 28.2% improvement from the -$1.03 loss posted in the year-ago period. The clinical-stage biotechnology company continues to burn cash as it advances its Versamune platform through development, though the narrowing deficit […]

UNCY|EPS -$1.67|Net Loss $26.6M Unicycive Therapeutics, Inc. (UNCY) posted FY 2025 basic and diluted EPS of -$1.67. Unicycive Therapeutics, Inc. is a Biotechnology company. Bottom line showed a net loss of $26.6M. Wall Street consensus stands at 10 buy, 1 hold, 0 sell. This article was generated with the assistance of AI technology and reviewed

USAR|EPS -$0.19|Rev $1.6M|Net Loss $50.5M USA Rare Earth, Inc. reported a loss of $0.19 per share for the fourth quarter of 2025, as the rare earth minerals developer continues to invest heavily in its operations. The company generated $1.6M in revenue for the quarter while posting a net loss of $50.5M for the period. The

BCAX|EPS -$0.68|Net Loss $37.4M Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. As a clinical-stage company, Bicara’s financial statements did not report any revenue for 2025. The company reported a basic and diluted Earnings Per Share (EPS) net loss of $(0.68) for the fourth quarter

PDSB|EPS -$0.74|Net Loss $34.5M PDS Biotechnology Corporation reported a full-year 2025 loss per share of -$0.74, marking a significant improvement from the year-ago period as the clinical-stage biopharmaceutical company continues to advance its pipeline of targeted cancer immunotherapies. The loss narrowed 28.2% compared to the -$1.03 per share loss recorded in FY 2024. The company

NMRA|EPS -$0.35|Net Loss $59.4M Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for brain diseases. Based on the provided financial statements, the company did not report any revenue for 2024 or 2025. The basic and diluted net loss per share (EPS) was $(1.45) for the full year 2025, an improvement from

USAS|EPS -$0.13 vs $0.04 est (-425.0%)|Rev $118.0M vs $65.3M est (+80.8%)|Net Loss $87.4M Americas Gold and Silver Corporation reported a loss of $0.13 per share for the full year of 2025, missing analyst expectations of $0.04 earnings per share by 425.0% based on estimates from 1 analyst. The mining company posted a net loss of